What we do Skybiotech Healthcare Limited, originally Kapil Cotex Limited, is engaged in textiles and pharmaceuticals via its subsidiary Skybiotech Lifescience Pvt Ltd. |
Founded in 1,983 |
Market share Recently restructured with 72.52% acquisition in pharmaceutical subsidiary, seeking growth in pharma sector with strong domestic and export potential. |
Problem solved Provides textile manufacturing and pharmaceutical products addressing medical and consumer needs, transitioning focus to pharma growth. |
Top clients or who we serve Serves textile and pharmaceutical industries, clients include foreign textile traders and pharmaceutical markets in India and abroad. B2B and B2C segments. |
Key management Poonam Prakash Rathi (Managing Director), Prakashchandra Rathi (Director and CFO) |
Our journey and innovations Incorporated in 1983 for textiles; in 2024 acquired majority stake in pharmaceutical company to diversify and innovate in healthcare. |
Where we operate Based in India with pharmaceutical products marketed domestically and internationally. |
Top products or what we offer Textile spinning, weaving, finishing; pharmaceutical manufacturing and distribution through subsidiary. |
Top brands - |
Raw materials needed Raw cotton and yarn for textiles; pharmaceutical raw materials sourced per product need. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily non-recurring from brokerage and capital gains; pharmaceutical subsidiary aims for recurring pharma sales. |
Our industry position Small player in textiles; emerging in pharmaceutical sector through subsidiary with growing market presence. |
Financial highlights Consolidated revenue of Rs. 705.18 Lakhs; consolidated loss of Rs. 236.89 Lakhs for FY 2024-25 post subsidiary acquisition. |
Geographical revenue split - |
Order book - |
Whats driving growth Pharmaceutical subsidiary acquisition driving growth; investment in pharma manufacturing amid growing market demand. |
Our future plans Expand pharmaceutical operations leveraging subsidiary; explore new growth avenues beyond existing textile business. |
Our green promise - |
Our people and values Board includes experienced directors; focus on compliance, corporate governance, and ethical business practices. |
Key challenges ahead Transition from textile to pharma business; achieving profitability and regulatory compliance in pharma sector. |
Interesting facts Company renamed to Skybiotech Healthcare Limited in 2025 to reflect new pharma focus; acquired controlling stake in pharma firm in 2024. |
Risks and strategy Managing transition risks from textiles to pharma; focus on risk mitigation through compliance and strategic investments. |
